Pentaxim supply delay weighs down Sanofi earnings

Just 6 months after problems at a Toronto plant for pertussis-containing vaccines sank Sanofi's ($SNY) earnings, the French drugmaker Tuesday reported another earnings slowdown thanks to a supply delay on Pentaxim. The delay, which hit in Mexico and China, dragged vaccine unit revenues down 4.2% to €628 million ($870.1 million) and contributed to total profit and sales tallies that missed analysts' marks. Release (PDF) | More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.